SUBSCRIBE
SUBSCRIBE

Tango Therapeutics

NEWS
Genetown
Rheos Medicines Launches with $60 Million
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
March 22, 2018
 · 
3 min read
 · 
Mark Terry
What You Need to Know About Tango Therapeutics
Business
What You Need to Know About Tango Therapeutics
Tango officially launched in 2017 and hit the ground running as a cancer drug target discovery and drug development company based on CRISPR technology.
December 13, 2017
 · 
5 min read
 · 
Mark Terry
NextGen Bio Class of 2018
Bio NC
Top 20 Life Science Startups to Watch in 2018
BioSpace is proud to present its NextGen “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
December 4, 2017
 · 
9 min read
 · 
Mark Terry
Interim CEO Named Permanent Leader at Tango Therapeutics
Business
Interim CEO Named Permanent Leader at Tango Therapeutics
September 25, 2017
 · 
3 min read
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Tango Therapeutics Officially Debuts With $55 Million and a Crew of Superstar Scientific Advisers
March 30, 2017
 · 
3 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
Third Rock Ventures Quietly Launches Tango Therapeutics in Editas Medicine’s HQ
March 7, 2017
 · 
2 min read
Load More
AWARDS
  • NextGen Class of 2018
JOBS
IN THE PRESS
Genetown
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024
April 1, 2024
 · 
2 min read
Business
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
March 18, 2024
 · 
15 min read
Genetown
Tango Therapeutics to Participate in Upcoming March 2024 Investor Conferences
March 6, 2024
 · 
1 min read
Genetown
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 5, 2024
 · 
7 min read
Genetown
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
January 31, 2024
 · 
1 min read
Genetown
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2024
January 5, 2024
 · 
2 min read
Drug Development
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
January 3, 2024
 · 
7 min read
Drug Development
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
November 13, 2023
 · 
8 min read
Business
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 8, 2023
 · 
15 min read
Genetown
Tango Therapeutics to Present at the Jefferies 2023 London Healthcare Conference
November 7, 2023
 · 
1 min read
Load More